Asahi Kasei Pharma Corp. v. Actelion Ltd.
California Court of Appeal
222 Cal. App. 4th 945 (2014)
- Written by Sean Carroll, JD
Facts
Asahi Kasei Pharma Corporation (Asahi) (plaintiff) signed a licensing contract with CoTherix, Inc. (CoTherix). The contract provided that CoTherix would assist Asahi with developing and marketing Asahi’s drug to treat pulmonary arterial hypertension (PAH). Actelion Limited (Actelion) (defendant) marketed a competing PAH drug. Actelion acquired CoTherix and informed Asahi that it would be discontinuing the development of Asahi’s drug. Asahi brought suit against Actelion and three Actelion executives for intentional interference with contractual relations. Asahi presented evidence that Actelion acquired CoTherix solely because it saw Asahi’s drug as a threat to Actelion’s market dominance. The trial court found in favor of Asahi and awarded Asahi almost $550 million in compensatory damages and $30 million in punitive damages. Actelion appealed, arguing that as of its acquisition of CoTherix it was no longer a disinterested third party to the Asahi-CoTherix contract. As a result, Actelion argued, it could not be liable for contractual interference as of that date.
Rule of Law
Issue
Holding and Reasoning (Bruiniers, J.)
What to do next…
Here's why 803,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 46,300 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.